CONGENITAL HYPERINSULINISM TREATMENT MARKET ANALYSIS

Congenital Hyperinsulinism Treatment Market, by Disease Type (KATP-HI, GDH-HI, GK-HI, Other (SCHAD HI,HNF4A/HNF1A, etc.)), by Drug Type (Diazoxide, Octreotide, Glucagon, Nifedipine, Other (Sirolimus, Chlorothiazide, etc.), by Route of Administration (Oral, Parenteral), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Published In : Nov 2022
Code : CMI5329
Pages :190
Formats :
Excel and PDF
Industry : Pharmaceutical

Market News

Global Congenital Hyperinsulinism Treatment Market: Key Developments

Glucagon, one of the primary medication of congenital hyperinsulinism shows promising results in treating congenital hyperinsulinism. For instance, in March 16, 2022, Xeris Pharmaceuticals, Inc., a biopharmaceutical company, develop a therapy for patients populations in endocrinology, a GVOKE kit (Glucagon Injection), containing liquid stable glucagon which is used to treat congenital hyperinsulinism. GVOKE was evaluated in a clinical trial in 31 pediatric patients with type 1 diabetes 100% (30/30) of pediatric patients had their glucose levels raise to safe levels.

This kit is indicated for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes ages 2 years and above.